BTK

Signaling Pathway Map

Research Area

  • Inhibitory Selectivity
  • Solubility
Catalog No. Product Name Solubility(25°C)
Water DMSO Alcohol
S2680 Ibrutinib (PCI-32765) <1 mg/mL 88 mg/mL 45 mg/mL
S7173 Spebrutinib (CC-292, AVL-292) <1 mg/mL 85 mg/mL <1 mg/mL
S7257 CNX-774 <1 mg/mL 100 mg/mL 2 mg/mL
S7080 RN486 <1 mg/mL 62 mg/mL <1 mg/mL
S7734 LFM-A13 <1 mg/mL 72 mg/mL <1 mg/mL
S8542 Btk inhibitor 2 <1 mg/mL 86 mg/mL 9 mg/mL
S8348 BMS-935177 <1 mg/mL 100 mg/mL 100 mg/mL
S7877 ONO-4059 analogue <1 mg/mL 20 mg/mL <1 mg/mL
S8294 Olmutinib (HM61713, BI 1482694) <1 mg/mL 97 mg/mL 23 mg/mL
S8116 Acalabrutinib (ACP-196) <1 mg/mL 93 mg/mL 93 mg/mL
S7051 CGI1746 <1 mg/mL 100 mg/mL 33 mg/mL
S8166 ONO-4059 (GS-4059) hydrochloride <1 mg/mL 98 mg/mL 1 mg/mL
Catalog No. Information Product Use Citations Product Validations
S2680

Ibrutinib (PCI-32765)

Ibrutinib (PCI-32765) is a potent and highly selective Brutons tyrosine kinase (Btk) inhibitor with IC50 of 0.5 nM in cell-free assays, modestly potent to Bmx, CSK, FGR, BRK, HCK, less potent to EGFR, Yes, ErbB2, JAK3, etc.

S7173

Spebrutinib (CC-292, AVL-292)

Spebrutinib (CC-292, AVL-292) is a covalent, orally active, and highly selective BTK inhibitor with IC50 of <0.5 nM, displaying at least 1400-fold selectivity over the other kinases assayed. Phase 1.

S7257

CNX-774

CNX-774 is an irreversible, orally active, and highly selective BTK inhibitor with IC50 of <1 nM.

S7080

RN486

RN486 is a potent and selective BTK inhibitor with IC50 of 4 nM.

S7734

LFM-A13

LFM-A13 is a specific Bruton's tyrosine kinase (BTK) inhibitor with IC50 of 2.5 μM, >100-fold selectivity over other protein kinases including JAK1, JAK2, HCK, EGFR,and IRK.

S8542New

Btk inhibitor 2

Btk inhibitor 2 is a BTK inhibitor.

S8348New

BMS-935177

BMS-935177 is a potent, reversible Bruton's Tyrosine Kinase (BTK) inhibitor with an IC50 value of 2.8 nM and demonstrates good kinase selectivity. It is more potent against BTK than other kinase, including the other Tec family kinases (TEC, BMX, ITK, and TXK) over which the compound is between 5- and 67-fold selective.

S7877

ONO-4059 analogue

ONO-4059 analogue is an analogue of ONO-4059, which is a highly potent and selective oral BTK inhibitor with IC50 of 23.9 nM. Phase 1.

S8294

Olmutinib (HM61713, BI 1482694)

Olmutinib is a novel third-generation epidermal growth factor receptor (EGFR) mutation-specific tyrosine kinase inhibitor (TKI). Also a potent inhibitor of Bruton's tyrosine kinase.

S8116

Acalabrutinib (ACP-196)

Acalabrutinib(ACP-196) is a selective second-generation Bruton's tyrosine kinase (BTK) inhibitor with an IC50 of 3 nM, which prevents the activation of the B-cell antigen receptor (BCR) signaling pathway. ACP-196 has improved target specificity over ibrutinib with 323-, 94-, 19- and 9-fold selectivity over the other TEC kinase family members (ITK, TXK, BMX, and TEC, respectively) and no activity against EGFR.

S7051

CGI1746

CGI1746 is a potent and highly selective small-molecule inhibitor of the Btk with IC50 of 1.9 nM.

S8166

ONO-4059 (GS-4059) hydrochloride

ONO-4059 (GS-4059) is highly potent and selective BTK inhibitor with an IC50 of 2.2 nM.